Cosmetic Research Analysis
In 2025-Q4, cosmetic research converged on mechanism-driven therapies, imaging-enabled procedural safety, and upstream platform innovations. High-level clinical evidence consolidated onabotulinumtoxinA as a durable non-surgical option for platysmal neck bands, while randomized data supported hydroquinone-sparing TXA/niacinamide regimens for melasma and a TRPM8 agonist cream for chronic prurigo. A translational redox study identified 5‑methoxytryptophan as both a hypoxia biomarker and Prdx6-targe